Emergent BioSolutions Expands NARCAN Nasal Spray Portfolio with FDA-Approved Multipacks
Event summary
- FDA approved Emergent BioSolutions' sNDA for 6-count and 24-count multipacks of NARCAN® Nasal Spray on February 12, 2026.
- New multipack configurations aim to improve distribution efficiency for high-volume naloxone programs.
- Over 85 million doses of NARCAN® Nasal Spray have been distributed since its 2016 prescription launch.
- Multipacks will be available through NARCANDirect®, Emergent’s proprietary ordering platform.
The big picture
The FDA approval of NARCAN® Nasal Spray multipacks aligns with broader efforts to combat the opioid crisis by improving naloxone distribution. Emergent BioSolutions' strategic focus on accessibility and usability underscores the growing importance of over-the-counter naloxone in public health preparedness. The move could also influence competitors to innovate in product formatting and distribution efficiency.
What we're watching
- Distribution Efficiency
- How the new multipack configurations will impact the cost-effectiveness and scalability of naloxone distribution programs.
- Market Penetration
- Whether the expanded product suite can further solidify NARCAN® Nasal Spray's position in the opioid overdose treatment market.
- Regulatory Dynamics
- The pace at which additional FDA approvals or policy changes could enhance naloxone accessibility.
Our editorial coverage:
Related topics